Partial replicate design: reference(s)? [RSABE / ABEL]

posted by ElMaestro  – Denmark, 2020-08-13 15:23 (252 d 22:43 ago) – Posting: # 21869
Views: 3,042

(edited by ElMaestro on 2020-08-13 15:43)

Hi Hötzi,

it is very interesting. I looked at Chow&Liu's 2009 version of the holy scriptures and they also seem not to mention RTR/RRT/TRR.

I can easily imagine that some innovator had a presub meeting with FDA (about which not much is in the public domain) and then the idea caught on in a rather un-public way and later got the nod from EMA. It is speculation of course but such things would often happen at the initiative in the private sector behind the curtains.
I don't recall the details of dossiers I assessed, I am fairly sure that I (incompetently, of course) assessed BE trials based on RTR/RRT/TRR designs from 2005 and onwards, but I am not 100% sure. Had I not sniffed all that glue, memories of the past would likely have been less foggy.

It might also be that one of the consortia like PQRI could have looked into the matter and released a white paper. I have no idea, but what a mystery :-)
My money is on Walter Hauck, if you can get hold of him, he will tell you where it all came from.

Update: Kamal Midha referred to it as ABE3 in a presentation from 2006.

Is there an easy way to download that thing, by the way????

Pass or fail!

Complete thread:

 Admin contact
21,429 posts in 4,479 threads, 1,512 registered users;
online 16 (1 registered, 15 guests [including 4 identified bots]).
Forum time: Friday 14:06 CEST (Europe/Vienna)

There is one certainty in drug development
and statistics that one can depend on:
the data are always late.    Scott Patterson and Byron Jones

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz